Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial

This study (n=755) found use of circulating tumour cell count to guide treatment (chemotherapy if ≥5/7.5mL; endocrine therapy if <5/7.5mL) was associated with similar progression-free survival to clinician-driven treatment (median 15.5 v 13.9 months; HR 0.94; 90% CI 0.81-1.09).

JAMA Oncology